Comments
Strides Pharma Science on Tuesday announced that its 50:50 joint venture Strides Vivimed Pte Ltd, Singapore, has received approval for albendazole tablets USP 200 mg from the United States Food & Drug Administration. This is the second generic approval by the US FDA for albendazole tablets, which is an anthelmintic medication used to treat certain infections caused by tapeworm. Albendazole prevents newly-hatched insect larvae (worms) from growing or multiplying in the body. According to IQVIA MAT data, the US market for albendazole tablets USP 200 mg is approximately $100 million. Shares of Strides Pharma Science jumped 6.6 per cent at ₹459.30 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.